Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2017

View Archived Issues

Medsenic's arsenic trioxide awarded E.U. orphan drug designation for GvHD, begins phase II trial

Novel prototypical peptidomimetic inhibitor demonstrates efficacy in models of AML

IMPDH inhibition as a promising new therapeutic strategy against MLL-fusion leukemia

AMPK identified as a novel therapeutic target in acute lymphoblastic leukemia

Researchers identify a novel target for AML and MDS

Xenikos obtains funding to support T-Guard development

Flamel Technologies now Avadel Pharmaceuticals

Axsome Therapeutics cleared to begin phase II/III study of AXS-05 in Alzheimer's

Bayer Pharma patents muscarinic acetylcholine M2 receptor PAMs

University of Florida discloses aminoacyl-tRNA synthetase inhibitors

Zynerba Pharmaceuticals commences FAB-C study of ZYN-002 gel

Abeona Therapeutics' ABO-201 granted orphan drug designation in Europe

Inventiva initiates patient enrollment in phase IIb study of IVA-337

Almirall describes JAK inhibitors

Soliqua available in U.S.

Adhaere Pharmaceuticals presents anticancer agents

Kite Pharma submits IND for phase I study of KITE-718

GSK closes agreement to divest non-core assets to Aspen

FDA grants priority review to Stivarga sNDA for hepatocellular carcinoma

Astellas Pharma discloses dopamine D1 receptor PAMs

Seattle Genetics presents new clinical data for vadastuximab talirine

Agile reports phase III topline results for Twirla hormonal contraceptive patch

Newron Pharmaceuticals reports promising results for evenamide in schizophrenia

Inspyr Therapeutics to study mipsagargin combination therapies

NewVac's phase II study of quisinostat meets primary endpoints

Inotek reports topline results from pivotal trial of trabodenoson for glaucoma

Acura explores financing and strategic alternatives

CymaBay Therapeutics signs license agreement with Kowa for arhalofenate in U.S.

Cellectis submits IND to begin phase I trials of UCART-123

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...